| Bid | 13.8 |
| Market Cap | 1.02B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.74 |
| PE Ratio (ttm) | -3.96 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 15.48 |
| Volume | 413,486 |
| Avg. Volume (20D) | 601,255 |
| Open | 15.29 |
| Previous Close | 15.16 |
| Day's Range | 14.71 - 15.43 |
| 52-Week Range | 12.17 - 28.67 |
| Beta | undefined |
About BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial ...
Analyst Forecast
According to 9 analyst ratings, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 115.92% from the latest price.
Next Earnings Release
Analysts project revenue of $5.34M, reflecting a 0.17% YoY growth and earnings per share of -0.88, making a -24.14% decrease YoY.
2 months ago · seekingalpha.com
Bicycle Therapeutics: Looking Again At An Intriguing Developmental ConcernToday, we revisit Bicycle Therapeutics plc, a clinical-stage biopharma firm, that has intriguing potential and focuses on developing medicines for unmet needs. The company is advancing several candida...
